Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Mary Linton B PetersAndrew L EckelClaudia L SeguinBarak DavidiDavid H HowardAmy B KnudsenPari V PandharipandePublished in: JCO oncology practice (2023)
Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.